VEA
BCAX

Virtus ETF Advisers’s Bicara Therapeutics BCAX Stock Holding History

Virtus ETF Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,939
Closed -$68.6K – 820
2024
Q4 		$68.6K Buy
+3,939
New +$82K 0.03% 390

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtus ETF Advisers's BCAX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Bicara Therapeutics (BCAX) in Q1 2025, closing a stake of 3,939 shares — an estimated $68.6K sold.

Virtus ETF Advisers first reported a position in BCAX in Q4 2024 and held it in 1 quarter. The position peaked at $68.6K in Q4 2024. 93 funds tracked by Wall St. Rank hold BCAX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Bicara Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,939 Bicara Therapeutics shares in Q1 2025, an estimated $68.6K.
  • Virtus ETF Advisers first reported a position in Bicara Therapeutics in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's Bicara Therapeutics position peaked at $68.6K in Q4 2024.
  • 93 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.